

Mabs with that of sialylGb5 by dot-blot immunostaining. Serially diluted sialylGb5 was dot-blotted onto a PVDF membrane, and the membrane was immunostained with the two Mabs. Both 6E2 and MC813-70 bound to more than 12 ng of sialylGb5, but the signals induced by 6E2 were stronger than those induced by MC813-70 (Fig. 2B,C). Thus, in addition to the flow cytometric analysis, the reactivity of 6E2 with sialylGb5 was stronger than that of MC813-70 by dot-blot immunostaining.

SSEA-4 Immunostaining of cynomolgus monkey ES cells

To confirm whether Mab 6E2 reacts with SSEA-4 on monkey ES cells, we performed an indirect immunofluorescence staining of cynomolgus monkey ES cells with Mab 6E2 and MC813-70. Mab 6E2 reacted with monkey ES cells (Fig. 3A) as well as MC-813-70 did (Fig. 3B). No difference in staining patterns of SSEA-4 between the two Mabs was observed. Mab 6E2 certainly stained SSEA-4 on monkey ES cells.

SSEA-4 immunostaining of "living" mouse preimplantation embryos without fixation

During early embryogenesis in mice, SSEA-4 had been reported to be expressed in fertilized eggs with levels gradually increasing to the morula stage and then decreasing [5]. Thus we examined the expression and distribution of SSEA-4 in preimplantation mouse embryos by immunostaining with both 6E2 and MC813-70. Both Mabs evenly stained the whole surface membranes of fixed mouse embryos, and no difference in staining pattern between the two was observed (data not shown). In order to perform a time-course of SSEA-4 distribution in a viable state, we performed immunostaining of preimplantation embryos without fixation.

3D-images of the 6E2 staining pattern obtained by confocal laser scanning microscopic observation clearly showed the localization of SSEA-4 on mouse preimplantation embryos. Two-cell embryos showed patches of SSEA-4 over the whole surface membrane with some accumulation at the interface between blastomeres (Fig. 4A). In 8-cell embryos, the amount accumulated at interfaces was further increased, as if planer membranes

separate each blastomere, and some large patches were internalized but others were left on the surface membranes (Fig. 4B). The amount of SSEA-4 concentrated at the interfaces in morula was not as significant as in 8-cell embryos but still clearly observed and some patches were internalized (Fig. 4C).

2D-images of embryos stained with 6E2 showed a marked accumulation of SSEA-4 at the interfaces between blastomeres (Fig. 4D–F). These results suggest that sialylGb5 actively moves during development and tends to accumulate where blastomeres come into contact with each other.

Interestingly, however, the staining pattern of SSEA-4 using MC813-70 was different from that using 6E2. MC813-70 evenly stained the surface and the interface between blastomeres of 2-cell embryos with patches (Fig. 4G), and the amount of SSEA-4 at interfaces was not significant (Fig. 4J). In 8-cell embryos, there were patches of SSEA-4 in the central area of the outer surface of each blastomere (Fig. 4H, indicated by arrows), but the 2D-image showed that clustering also occurred at surfaces facing blastocoels (Fig. 4K, indicated by arrowheads). In morula embryos, SSEA-4 was distributed on the surface in patches and was enriched at the boundaries between blastomeres on the outer surface (Fig. 4I,L).

It remains unclear why the pattern of staining of mouse preimplantation embryos differs between 6E2 and MC813-70. The composition of fatty acids in GSLs influences the binding of antibodies [16,17] or bacterial toxins [18]. SialylGb5 recognized by the two Mabs might differ in composition of fatty acids, resulting in different immunostaining patterns. It was reported that the clustering of sialylGb5 by a Mab induces the activation of sialylGb5-associated kinases in raft microdomains of human mammary carcinoma cells, leading to downstream signaling [19,20]. The clustering of sialylGb5 by 6E2 on preimplantation mouse embryos may also induce the activation of some kinases followed by downstream signaling. Recently, Comisk et al. suggested that lipid rafts and their associated molecules are spatiotemporally positioned to play a critical role in preimplantation developmental events [21]. The patches or clusters of sialylGb5 shown in our study suggest the presence of lipid rafts containing sialylGb5 on mouse embryos.




Fig. 3. Indirect immunostaining of cynomolgus monkey ES cell line CMK-6 with 6E2 and MC813-70. The CMK-6 cells were stained with 6E2 (A), MC813-70 (B), or isotype-matched mouse IgG (C), and visualized with secondary antibodies (green), followed by counterstaining of nuclei with DAPI (blue). Scale bars = 200 μ m.




Fig. 4. Immunostaining of SSEA-4 on mouse preimplantation embryos with 6E2 and MC813-70. The embryos at the 2-cell (A, D, G, J), the 8-cell (B, E, H, K), and the morula (C, F, I, L) stages were stained with 6E2 (green) or MC813-70 (red). The panels designated 3D (A, B, C, G, H, I) are three-dimensional images reconstructed by stacking optical slice images using LSM software and the panels designated 2D (D, E, F, J, K, L) are an overlay of a fluorescent image and a differential interference contrast micrograph. Scale bars = 20 μ m.

6E2 has high affinity for sialylGb5 and can be effectively conjugated with fluorescence reagents, leading to excellent staining of SSEA-4 in the surface membrane of "living" mouse preimplantation embryos. 6E2 should be of use for research into lipid rafts in early development and of great advantage for the characterization of ES cells and EC cells.

Acknowledgments

We thank S. Yamauchi for her excellent secretarial work. This work was supported in part by grants from CREST of JST and the 3rd. term comprehensive 10-year-strategy for cancer control, Research on Children and Families, Research on Human Genome Tailor made and Research on Publicly Essential Drugs and Medical Devices, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan and a grant from The Japan Leukemia Research Field.

References

- [1] B. Mintz, K. Illmensee, Normal genetically mosaic mice produced from malignant teratocarcinoma cells, *Proc. Natl. Acad. Sci. USA* 72 (1975) 3585–3589.
- [2] P.W. Andrews, I. Damjanov, D. Simon, G.S. Banting, C. Carlin, N.C. Dracopoli, J. Fogh, Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro, *Lab Invest.* 50 (1984) 147–162.
- [3] J.F. Jun-ichi Hata, Eizaburo Ishii, Akihiro Umezawa, Yasuo Kokai, Yoshie Matsubayashi, Hiroshi Abe, Satoru Kusakari, Haruto Kikuchi, Taketo Yamada, Tatsuya Maruyama, Differentiation of human germ cell tumor cells *in vivo* and *in vitro*, *Acta Histochem. Cytochem.* 25 (1992) 563–576.
- [4] J.S. Draper, C. Pigott, J.A. Thomson, P.W. Andrews, Surface antigens of human embryonic stem cells: changes upon differentiation in culture, *J. Anat.* 200 (2002) 249–258.
- [5] T. Muramatsu, H. Muramatsu, Carbohydrate antigens expressed on stem cells and early embryonic cells, *Glycoconj. J.* 21 (2004) 41–45.
- [6] T. Nakano, A. Umezawa, H. Abe, N. Suzuki, T. Yamada, S. Nozawa, J. Hata, A monoclonal antibody that specifically reacts with human embryonal carcinomas, spermatogonia and oocytes is able to induce human EC cell death, *Differentiation* 58 (1995) 233–240.
- [7] M. Yamamoto, N. Tase, T. Okuno, Y. Kondo, S. Akiba, N. Shimozawa, K. Terao, Monitoring of gene expression in differentiation of embryoid bodies from cynomolgus monkey embryonic stem cells in the presence of bisphenol A, *J. Toxicol. Sci.* 32 (2007) 301–310.
- [8] Y.U. Katagiri, K. Ohmi, C. Katagiri, T. Sekino, H. Nakajima, T. Ebata, N. Kiyokawa, J. Fujimoto, Prominent immunogenicity of monosialosyl galactosylglycoside, carrying a stage-specific embryonic antigen-4 (SSEA-4) epitope in the ACHN human renal tubular cell line—a simple method for producing monoclonal antibodies against detergent-insoluble microdomains/raft, *Glycoconj. J.* 18 (2001) 347–353.
- [9] Y.U. Katagiri, N. Kiyokawa, K. Nakamura, H. Takenouchi, T. Taguchi, H. Okita, A. Umezawa, J. Fujimoto, Laminin binding protein, 34/67 laminin receptor, carries stage-specific embryonic antigen-4 epitope defined by monoclonal antibody Raft.2, *Biochem. Biophys. Res. Commun.* 332 (2005) 1004–1011.
- [10] K. Nakamura, Y. Hashimoto, M. Suzuki, A. Suzuki, T. Yamakawa, Characterization of GM1b in mouse spleen, *J. Biochem. (Tokyo)* 96 (1984) 949–957.
- [11] The nomenclature of lipids (recommendations 1976). IUPAC-IUB Commission on Biochemical Nomenclature, *J. Lipid. Res.* 19 (1978) 114–128.
- [12] L. Svennerholm, Designation and schematic structure of gangliosides and allied glycosphingolipids, *Prog. Brain Res.* 101 (1994) XI–XIV.
- [13] L.L. Cooling, K. Kelly, Inverse expression of P(k) and Luke blood group antigens on human RBCs, *Transfusion* 41 (2001) 898–907.
- [14] L.H. Shevinsky, B.B. Knowles, I. Damjanov, D. Solter, Monoclonal antibody to murine embryos defines a stage-specific embryonic antigen expressed on mouse embryos and human teratocarcinoma cells, *Cell* 30 (1982) 697–705.
- [15] L. Cooling, D. Hwang, Monoclonal antibody B2, a marker of neuroendocrine sympathoadrenal precursors, recognizes the Luke (LKE) antigen, *Transfusion* 45 (2005) 709–716.
- [16] K. Iwabuchi, I. Nagaoka, Lactosylceramide-enriched glycosphingolipid signaling domain mediates superoxide generation from human neutrophils, *Blood* 100 (2002) 1454–1464.
- [17] K. Iwabuchi, Y. Zhang, K. Handa, D.A. Withers, P. Sinay, S. Hakomori, Reconstitution of membranes simulating "glycosignaling

- domain" and their susceptibility to lyso-GM3, *J. Biol. Chem.* 275 (2000) 15174–15181.
- [18] A. Kiarash, B. Boyd, C.A. Lingwood, Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin I and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues, *J. Biol. Chem.* 269 (1994) 11138–11146.
- [19] W.F. Steelant, Y. Kawakami, A. Ito, K. Handa, E.A. Bruyneel, M. Mareel, S. Hakomori, Monosialyl-Gb5 organized with cSrc and FAK in GEM of human breast carcinoma MCF-7 cells defines their invasive properties, *FEBS Lett.* 531 (2002) 93–98.
- [20] S. Van Slambrouck, W.F. Steelant, Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells, *Biochem. J.* 401 (2007) 689–699.
- [21] M. Comiskey, C.M. Warner, Spatio-temporal localization of membrane lipid rafts in mouse oocytes and cleaving preimplantation embryos, *Dev. Biol.* 303 (2007) 727–739.

Eye-open at birth phenotype with reduced keratinocyte motility in *LGR4* null mice

Shigeki Kato^{a,1}, Yasuaki Mohri^a, Tsuyoshi Matsuo^a, Eisaku Ogawa^b, Akihiro Umezawa^c,
Ryuhei Okuyama^b, Katsuhiko Nishimori^{a,*}

^a Laboratory of Molecular Biology, Graduate School of Agricultural Science, Tohoku University, 1-1 Tsutsumidori-Amamiyamachi, Aoba-ku, Sendai 981-8555, Japan

^b Department of Dermatology, Tohoku University Graduate School of Medicine, 2-1 Seiryō-machi, Aoba-ku, Sendai 980-8574, Japan

^c National Research Institute for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo 157-8535, Japan

Received 30 July 2007; accepted 27 August 2007

Available online 4 September 2007

Edited by Ned Mantei

Abstract We observed a consistent eye-open at birth (EOB) phenotype in mouse pups homozygous for a leucine-rich repeat containing G-protein coupled receptor 4 (*Lgr4*) allele deleting the whole transmembrane domain coding region. An *in vitro* wound-healing scratch assay showed notably reduced keratinocyte motility in the null mice. Phalloidin staining of F-actin in the eyelid epidermis was also reduced. We also generated keratinocyte-specific *Lgr4* deficient mice, circumventing the embryonic/neonatal lethality and kidney abnormalities. Most of the conditional *Lgr4* knockout mice showed the EOB phenotype. Thus, *Lgr4* might be a novel gene class regulating cell motility. © 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Keywords: LGR4; GPR48; GPCR; Gene deletion mice; EOB; Keratinocyte

1. Introduction

Lgr4 (leucine-rich repeat containing G-protein coupled receptor 4) is one of the genes identified as novel G-protein coupled receptors (GPCRs) [1,2], designated *Lgr4*–*Lgr8*, from an EST database with high homology to glycoprotein hormone receptors including follicle-stimulating hormone receptor (FSHR) [3], luteinizing hormone/chorionic gonadotropin receptor (LH/CGR) [4,5] and thyroid-stimulating hormone receptor (TSHR) [6].

As *Lgr4* shows high homology with FSHR, LHR and TSHR, this receptor has been thought to be involved in reproductive systems. Mazerbourg et al. reported the generation of

Lgr4 gene-interrupted mice using a gene-trapped ES cell line [7], in which the expression of *Lgr4* is severely attenuated by the insertion of the β -geo gene in an enhancer trap procedure [8]. They described the neonatal lethality of the null mice, but not the cause. Previously, we generated similar *Lgr4* knockout mice by completely removing exon18, which encodes the whole transmembrane domain of *Lgr4*, in order to eliminate the chance of receptor fragment localizing at the membrane or transmitting downstream signals [9]. In those *Lgr4* knockout mice, gross hypomorphic phenotypes developed in multiple tissues and organs, and the null mice showed hypoplastic kidneys with an increased concentration of plasma creatinine, which was strongly suspected to be the cause of the neonatal/embryonic lethality.

Recently, Mendive et al. as well as Hoshii et al. reported *Lgr4* gene-trap lines exhibiting defective postnatal development of the male reproductive tract [10,11], again in contrast to the embryonic/neonatal lethality seen in our *Lgr4* knockout mice on a 129Ola \times C57BL/6 hybrid background [9]. In our *Lgr4* knockout mice it appeared that complete loss of the *Lgr4* gene would induce complete embryonic/neonatal lethality. As reported in our first paper, the typical phenotype of the *Lgr4* null mutants other than the kidney aberration was eye open at birth (EOB) with 100% penetrance, strongly suggesting reduced keratinocyte proliferation and motility. Several studies have reported a strong relationship between a reduction in keratinocyte proliferation/motility and the EOB phenotype [12,13], and it has been suggested that *Lgr4* is essential for organ development and cancer cell invasion [10,11,14]. Additionally, a close relationship between cancer cell invasion and cell motility was reported, and it is well known that organ development requires cell motility [15,16]. We therefore suspected the existence of a close relationship between *Lgr4* and cell motility, and considered that common mechanisms might cause EOB and the other abnormalities observed in *Lgr4* null mice. In the present study we focused on the EOB phenotype in relation to the keratinocyte motility of the null mice.

We provide evidence that *Lgr4* has a role in keratinocyte motility. In addition, we succeeded in dissociating the EOB phenotype, first observed in all conventional *Lgr4* KO mice, from the kidney lesions and lethality using conditional *Lgr4* knockout mice crossed with K5-Cre transgenic mice.

*Corresponding author. Fax: +81 22 717 8883.

E-mail address: knishimo@mail.tains.tohoku.ac.jp (K. Nishimori).

¹Present address: Department of Molecular Genetics, Institute of Biomedical Sciences, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.

Abbreviations: LGR, leucine-rich repeat containing G-protein coupled receptor; GPCR, G-protein coupled receptor; FSHR, follicle-stimulating hormone receptor; LH/CGR, luteinizing hormone/chorionic gonadotropin receptor; TSHR, thyroid-stimulating hormone receptor; EOB, eye-open at birth; Arbp, acidic ribosomal phosphoprotein PO

2. Materials and methods

2.1. Histology

For the eyelid histology, the heads of the mice were fixed in 4% paraformaldehyde overnight. After dehydration, they were embedded in paraffin. Paraffin blocks were sectioned at 2–5 μm thickness and stained with H&E (hematoxylin–eosin) and Phalloidin-TRITC (tetramethyl rhodamine isothiocyanate) using standard procedures.

2.2. In vitro apoptosis cell test

Sections from around the eyelids of E15.5 mice were used for the detection of apoptotic cells. Samples were processed according to the protocol of In Situ Cell Death Detection Kit (Roche, Japan).

2.3. Keratinocyte primary culture

Primary keratinocytes were isolated from neonatal mice. The epidermis was separated from the dermis with 0.8 U/ml dispase (Roche) overnight at 4 °C. Keratinocytes were dissociated by trypsin for 5 min at 34 °C and plated onto dishes precoated with collagen type I. The cells were cultured in minimum essential medium supplemented with 4% Chelex (Bio-Rad, Hercules, CA)-treated fetal calf serum epidermal growth factor (10 ng/ml; Gibco BRL), and 0.05 mM CaCl_2 at 34 °C in an 8% CO_2 incubator. Under these conditions, keratinocytes are maintained in an immature state characterized by active proliferation. For all the experiments, the cells were used one week after plating.

2.4. In vitro migration assay

Keratinocytes derived from each genotype of neonatal mice were cultured until confluent. After scratching with plastic tips, the distance that the keratinocyte migrated was measured every 3 h. Each sample was counted at 16 points and the average distance was calculated.

2.5. Quantitative RT-PCR

Messenger RNA derived from wild-type and *Lgr4* null mice keratinocyte was subjected to cDNA synthesis by standard procedures. Quantitative RT-PCR assays were performed with the DNA Engine Opticon System (MJ Research, Japan) with a cycling profile as follows: at 95 °C for 2 min, 39 cycles at 95 °C for 5 s, at 61.4 °C for 30 s, and at 72 °C for 30 s. The genes and primer sets are shown in the supplementary material.

2.6. Generation of keratinocyte specific *Lgr4* deficient mice

To generate *Lgr4* *fx/fx* mice without *frt-Neo-frt* cassette, an initially targeted *Lgr4* mutant [9] was mated with Flp deleter [17]. Mice with the keratinocyte-specific *Lgr4* deletion were generated by breeding keratin5-Cre (*K5-Cre*); *Lgr4* *+/-* mice with *Lgr4* *fx/fx* mice [18]. The genetic backgrounds were C57Bl/6 \times 129Ola for *Lgr4* *+/-* and *Lgr4* *fx/fx*, and C57Bl/6 \times C3H for *K5-Cre*. Primers for *Lgr4* genotyping are shown in the supplementary material.

2.7. Statistical evaluation

All experimental data are expressed as mean \pm S.E.M. Statistical comparisons in all the physiological and laboratory data were made among the genotype groups using ANOVA followed by Student's *t*-test for individual comparisons. *P* values of <0.05 were considered significant.

3. Results

3.1. *Lgr4* null mice show morphological abnormalities in the eyelids at E15.5

Lgr4 null mice showed some gross abnormalities. In wild-type mice during the embryonic stages E15.5 through E16.5, epithelial cells extended to the center of the eyes and finally became fused. The mice were then born with their eyelids fused, and the eyelids opened gradually by 12–14 days after birth. However, *Lgr4* null mice showed the EOB phenotype with 100% penetrance (Fig. 1A). Histological analysis of the wild-type mice followed by immunostaining showed a high expres-




Fig. 1. *Lgr4* deficiency causes impairment in embryonic eyelid closure. (A) Left panel and right panel show morphology around eyes of *Lgr4* heterozygous (*Lgr4* *+/-*) and *Lgr4* null mice, respectively at postnatal day 0. (B) Eyelid sections prepared from E 15.5 wild-type (a, b) or null (c, d) mouse fetuses were immunostained with rabbit anti-LGR4 antibody (ab 12576, Abcam, USA), followed by HRP-conjugated second antibody. Asterisks show epithelial cell layer at the protruding tips of the growing eyelids, and arrows show the corneal epithelium layer. (C) Histological analysis (H&E staining) of E15.5 and E16.5 embryos.

sion level of *Lgr4* at the protruding tips of the eyelids and in the epithelial cells of the cornea at E15.5, but no expression was detected in the same areas of the null mice (Fig. 1B). As shown in Fig. 1C right, the eyelid closure was impaired in the null mice as compared to the heterozygous mice (Fig. 1C, left).

3.2. Proliferation and motility of keratinocytes from *Lgr4* null mice

EOB has been reported as a typical phenotype reflecting keratinocyte proliferation/motility, which we then measured. No decrease in proliferating cells was detected in the eyelid epi-

thelium of the null mutants at E15.5 (data not shown). Since a reduction of the cytoplasmic accumulation of F-actin was observed with the EOB phenotype in some gene knockout studies [19,20], we stained the eyelid sections with phalloidin and found that there was less filamentous accumulation of F-actin at the margin of the eyelid epithelium, as shown in Fig. 2A. Furthermore, we examined the extent of keratinocyte proliferation in vitro using the incorporation of BrdU, but no significant difference between the wild-type and the *Lgr4* null mice was observed (date not shown). Next, the keratinocyte motility was measured by an in vitro migration assay. The lack of *Lgr4* was related to a reduction of the keratinocyte motility, and we observed a significant delay in healing 3 hours after scratching in the cells from the null mice (Fig. 2B and C). To further analyze other possible mechanisms responsible for EOB in addition to the reduced motility of the null mice, wild-type and *Lgr4* null fetuses at E15.5 were subjected to TUNEL assay to examine the extent of cell apoptosis around the eyelid tissues. However, neither types of embryos showed any apoptotic cells (Fig. 2D).

These results suggest that the EOB observed in the null mice was not induced by an enhancement of apoptosis, and provide further evidence that *Lgr4* is a critical regulator for keratinocyte motility in the epidermal tissue of eyelids.

3.3. Quantitative RT-PCR of EOB related genes in keratinocytes from *Lgr4* null mice

The disruption of *EGFR*, *EGF*, *TGF- α* , *ADAM17*, *c-jun*, *ActivinA* and *ActivinB* genes has been reported to cause EOB. We measured the expression levels of these genes in mRNA prepared from wild-type and *Lgr4* null keratinocytes, but did not detect any significant differences in their expression levels (Fig. 3). In addition, the expression level of *EGFR* around the eyelid at E15.5 in the null mutants was normal (Supplementary Fig. S1). The phosphorylation of *EGFR* around the eyelid at E15.5 was examined in wild-type and *Lgr4* null mice by immunostaining, but no significant difference was observed (date not shown). The phosphorylation of *ERK* and *JNK* of the same samples also showed no difference (Supplementary Fig.S1).

3.4. Generation of keratinocyte-specific *Lgr4* deficient mice

As mentioned above, the EOB phenotype observed in *Lgr4* null mice was suspected to be closely related to reduced keratinocyte motility. We previously reported that *Lgr4* null mice showed renal hypoplasia [9]. To separate the EOB phenotype from the renal hypoplasia observed in *Lgr4* null mice, we additionally generated keratinocyte-specific *Lgr4* deficient mice (*Lgr4* conditional knockout mice) as described in Section 2




Fig. 2. EOB phenotype and impaired keratinocyte motility. (A) Coronal eye sections of E15.5 wild-type (*Lgr4* +/+) and null fetuses were stained with phalloidin-TRITC. Scale bar: 30 μ m. (B) Keratinocyte motility was assessed by in vitro wound-healing scratch assay, and values representing the mean (S.E.M.; vertical bar) of 16 independent wounds are shown by a linegraph (C). (*; $P < 0.005$, **; $P < 0.001$) (D) Neither wild-type nor *Lgr4* null E15.5 fetuses showed apoptotic cells in the eyelids. Positive control is tissue treated with DNase I. Scale bar: 60 μ m.




Fig. 3. Quantitative RT-PCR for cell motility-related genes. EGFR, EGF, TGF- α , c-jun, ADAM17, ActivinA and ActivinB mRNA levels in keratinocyte derived from *Lgr4* wild-type and null mice (P0) were quantified (all bars; $n = 3$). Error bars represent \pm S.E.M.

(Supplementary Fig. S2A and B). The keratinocyte-specific deletion of *Lgr4* gene in *Lgr4* conditional knockout mice was confirmed by RT-PCR (Fig. 4A). The *Lgr4* conditional knockout mice were spared the embryonic/neonatal lethality (data not shown) and almost all of them showed the EOB phenotype (Fig. 4B and C). The body size and weight of several organs

including the kidneys and liver were all reduced in *Lgr4* null mice [9], whereas those of the conditional knockout mice were all normal (Fig. 4D and E).

4. Discussion

In this report, we demonstrated an abnormality in the motility of keratinocytes and the EOB phenotype in *Lgr4* null mice. It is known that, during normal mouse development, the epithelial cells on the protruding tips of both the upper and lower eyelids migrate along the surface of the cornea and fuse with each other by E16.5 [12]. This suggests that EOB could be due to a defect in prenatal eyelid extension. EOB has been reported as a typical phenotype in mutant mice lacking several genes affecting epithelial cell proliferation and motility [12,13]. The genes whose deletion results in EOB include transcription factors controlling cell proliferation (c-jun [21,22]), growth factors (FGF10 [23], HB-EGF [20,24], TGF- α [25], ActivinB [26]) and their receptors (EGFR [27]), and related cytoplasmic factors functioning in signal transduction pathways (MEKK1 [28,29], JNK [30]). Xia et al. reviewed the signaling pathways required for embryonic eyelid closure in normal developmental stages and classified these into two major signaling pathways, TGF β /activin-MEKK1-JNK/p38 and TGF- α /EGFR-ERK [13]. Our data strongly suggest that *Lgr4* plays a critical role in regulating the formation of eyelids in the embryonic stage and that it contributes to epithelial cell motility. In addition, epidermal wound-healing activity [21,27] and tumorigenesis require epithelial cell motility [29]. Although the downstream signaling mechanisms of *Lgr4* are not clear, we speculate that a novel signaling pathway exists in keratinocytes to regulate the cell motility.

We generated *Lgr4* conditional knockout mice that were spared the embryonic/neonatal lethality, reduced body weight and renal hypoplasia observed in *Lgr4* null mice, and were born with a mendelian distribution. However, almost all of these mice showed the EOB phenotype. These results strongly suggest that the keratinocyte aberration shown by *Lgr4* null mice was not induced by renal hypoplasia.

The observed impairment in keratinocyte motility may suggest that *Lgr4* controls the cell motility of keratinocytes. In this context, elucidating the precise role of *Lgr4* along with its cognate ligand would advance the knowledge of the epithelial cell motility mechanism. Interestingly, one of our *Lgr4* null mice survived for more than 40 days, showing turbid corneas in addition to various defects. Microscopic observation of the cornea showed many stripes (data not shown), and we presume that the degeneration of the cornea, including wounds, resulted from excoriation by the floor material in the cage because of the EOB. However, immunostaining of the eye tissue clearly showed positive staining at the cornea in the wild-type mice in addition to the signal at the protruding tips of the eyelid (Fig. 1B). This result also suggests the possibility that the turbid cornea observed in null mice might be caused by a deficiency of the *Lgr4* gene. Therefore, a cornea-specific deletion of *Lgr4* will be required to study further the function of *Lgr4* in the development, growth and maintenance of the cornea tissue. To our knowledge, there are no published reports of EOB caused by a deficiency of GPCR genes. In addition, in the other reports on the generation of *Lgr4* mutants (by insertion of a gene cassette carrying a splice acceptor into an intron of




Fig. 4. Characteristics of *Lgr4* conditional knockout mice. (A) RT-PCR for *Lgr4* showed no expression of *Lgr4* mRNA in keratinocytes. Primer sets are shown in the supplementary material. (B) *Lgr4* conditional knockout mice show the typical EOB phenotype. (C) As in the case of *Lgr4* null mice, almost all of the *Lgr4* conditional knockout mice show the EOB phenotype. The body weight (D) and the organ weight of the liver and kidneys (E) of *Lgr4* conditional knockout mice are all within normal ranges.

the gene) on several genetic backgrounds [8,10,11], the EOB phenotype of the null mice was not described except in one abstract for a poster presentation [31]. Nevertheless, we predicted that *Lgr4* and its unidentified ligand(s) would likely be related to regulatory mechanisms controlling the development and maintenance of epidermal tissue including that of the eyelid.

In conclusion, we generated two mouse models, one with a complete deletion of the *Lgr4* function and another with a conditional *Lgr4* knockout, and provide evidence that *Lgr4* is involved in keratinocyte motility affecting eyelid formation. Adult conditional *Lgr4* knockout mice will be a useful tool for examining the *Lgr4* function in keratinocytes.

Acknowledgements: We would like to thank Dr. J. Takeda for providing us the K5 Cre TG mice, and Dr. M. Kitagawa for valuable discussion. This research was supported in part by a Grants-in-Aid for Exploratory Research (#17659251) from the Ministry of education, Culture, Sports, Science and Technology of Japan, and by a donation from Kureha Corporation.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.febslet.2007.08.064.

References

- [1] Hsu, S.Y., Liang, S.G. and Hsueh, A.J. (1998) Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region. *Mol. Endocrinol.* 12, 1830–1845.
- [2] Loh, E.D., Broussard, S.R., Liu, Q., Copeland, N.G., Gilbert, D.J., Jenkins, N.A. and Kolakowski Jr., L.F. (2000) Chromosomal localization of GPR48, a novel glycoprotein hormone receptor like GPCR, in human and mouse with radiation hybrid and interspecific backcross mapping. *Cytogenet. Cell. Genet.* 89, 2–5.
- [3] Baker, P.J., Pakarinen, P., Huhtaniemi, I.T., Abel, M.H., Charlton, H.M., Kumar, T.R. and O'Shaughnessy, P.J. (2003) Failure of normal Leydig cell development in follicle-stimulating hormone (FSH) receptor-deficient mice, but not FSHbeta-deficient mice: role for constitutive FSH receptor activity. *Endocrinology* 144, 138–145.
- [4] Huhtaniemi, I., Zhang, F.P., Kero, J., Hamalainen, T. and Poutanen, M. (2002) Transgenic and knockout mouse models for the study of luteinizing hormone and luteinizing hormone receptor function. *Mol. Cell. Endocrinol.* 187, 49–56.
- [5] Zhang, F.P., Poutanen, M., Wilbertz, J. and Huhtaniemi, I. (2001) Normal prenatal but arrested postnatal sexual development of luteinizing hormone receptor knockout (LuRKO) mice. *Mol. Endocrinol.* 15, 172–183.
- [6] Postiglione, M.P., Parlato, R., Rodriguez-Mallon, A., Rosica, A., Mithbaokar, P., Maresca, M., Marians, R.C., Davies, T.F., Zannini, M.S., De Felice, M. and Di Lauro, R. (2002) Role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland. *Proc. Natl. Acad. Sci. USA* 99, 15462–15467.
- [7] Leighton, P.A., Mitchell, K.J., Goodrich, L.V., Lu, X., Pinson, K., Scherz, P., Skarnes, W.C. and Tessier-Lavigne, M. (2001) Defining brain wiring patterns and mechanisms through gene trapping in mice. *Nature* 410, 174–179.
- [8] Mazerbourg, S., Bouley, D.M., Sudo, S., Klein, C.A., Zhang, J.V., Kawamura, K., Goodrich, L.V., Rayburn, H., Tessier-Lavigne, M. and Hsueh, A.J. (2004) Leucine-rich repeat-containing, G protein-coupled receptor 4 null mice exhibit intrauterine growth retardation associated with embryonic and perinatal lethality. *Mol. Endocrinol.* 18, 2241–2254.
- [9] Kato, S., Matsubara, M., Matsuo, T., Mohri, Y., Kazama, I., Hatano, R., Umezawa, A. and Nishimori, K. (2006) Leucine-rich repeat-containing G protein-coupled receptor-4 (LGR4, Gpr48) is essential for renal development in mice. *Nephron Exp. Nephrol.* 104, e63–e75.
- [10] Mendive, F., Laurent, P., Van Schoore, G., Skarnes, W., Pochet, R. and Vassart, G. (2006) Defective postnatal development of the male reproductive tract in LGR4 knockout mice. *Dev. Biol.* 290, 421–434.
- [11] Hoshii, T., Takeo, T., Nakagata, N., Takeya, M., Araki, K. and Yamamura, K. (2007) LGR4 regulates the postnatal development and integrity of male reproductive tracts in mice. *Biol. Reprod.* 76, 303–313.
- [12] Xia, Y. and Karin, M. (2004) The control of cell motility and epithelial morphogenesis by Jun kinases. *Trends Cell. Biol.* 14, 94–101.
- [13] Xia, Y. and Kao, W.W. (2004) The signaling pathways in tissue morphogenesis: a lesson from mice with eye-open at birth phenotype. *Biochem. Pharmacol.* 68, 997–1001.
- [14] Gao, Y., Kitagawa, K., Hiramatsu, Y., Kikuchi, H., Isobe, T., Shimada, M., Uchida, C., Hattori, T., Oda, T., Nakayama, K., Nakayama, K.I., Tanaka, T., Konno, H. and Kitagawa, M. (2007) Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis. *Cancer Res.* 66, 11623–11631.
- [15] Keller, R. (2002) Shaping the vertebrate body plan by polarized embryonic cell movements. *Science* 298, 1950–1954.
- [16] Sahai, E. (2005) Mechanisms of cancer cell invasion. *Curr. Opin. Genet. Dev.* 15, 87–96.
- [17] Rodriguez, C.I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., Stewart, A.F. and Dymecki, S.M. (2000) High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. *Nat. Genet.* 25 (2), 139–140.
- [18] Tarutani, M., Itami, S., Okabe, M., Ikawa, M., Tezuka, T., Yoshikawa, K., Kinoshita, T. and Takeda, J. (1997) Tissue-specific knockout of the mouse *Pig-a* gene reveals important roles for GPI-anchored proteins in skin development. *Proc. Natl. Acad. Sci. USA* 94, 7400–7405.
- [19] Mine, N., Iwamoto, R. and Mekada, E. (2005) HB-EGF promotes epithelial cell migration in eyelid development. *Development* 132, 4317–4326.
- [20] Shimizu, Y., Thumkeo, D., Keel, J., Ishizaki, T., Oshima, H., Oshima, M., Noda, Y., Matsumura, F., Taketo, M.M. and Narumiya, S. (2005) ROCK-1 regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. *J. Cell Biol.* 168, 941–953.
- [21] Li, G., Gustafson-Brown, C., Hanks, S.K., Nason, K., Arbeit, J.M., Pogliano, K., Wisdom, R.M. and Johnson, R.S. (2003) c-Jun is essential for organization of the epidermal leading edge. *Dev. Cell.* 4, 865–877.
- [22] Zenz, R., Scheuch, H., Martin, P., Frank, C., Eferl, R., Kenner, L., Sibilia, M. and Wagner, E.F. (2003) c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. *Dev. Cell.* 4, 879–889.
- [23] Tao, H., Shimizu, M., Kusumoto, R., Ono, K., Noji, S. and Ohuchi, H. (2005) A dual role of FGF10 in proliferation and coordinated migration of epithelial leading edge cells during mouse eyelid development. *Development* 132, 3217–3230.
- [24] Shirakata, Y., Kimura, R., Nanba, D., Iwamoto, R., Tokumaru, S., Morimoto, C., Yokota, K., Nakamura, M., Sayama, K., Mekada, E., Higashiyama, S. and Hashimoto, K. (2005) Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing. *J. Cell. Sci.* 118, 2363–2370.
- [25] Luetteke, N.C., Qiu, T.H., Peiffer, R.L., Oliver, P., Smithies, O. and Lee, D.C. (1993) TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. *Cell* 73, 263–278.
- [26] Vassalli, A., Matzuk, M.M., Gardner, H.A., Lee, K.F. and Jaenisch, R. (1994) Activin/inhibin beta B subunit gene disruption leads to defects in eyelid development and female reproduction. *Genes Dev.* 8, 414–427.
- [27] Miettinen, P.J., Berger, J.E., Meneses, J., Phung, Y., Pedersen, R.A., Werb, Z. and Derynck, R. (1995) Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. *Nature* 376, 337–341.
- [28] Yujiri, T., Ware, M., Widmann, C., Oyer, R., Russell, D., Chan, E., Zaitis, Y., Clarke, P., Tyler, K., Oka, Y., Fanger, G.R., Henson, P. and Johnson, G.L. (2000) MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation. *Proc. Natl. Acad. Sci. USA* 97, 7272–7277.
- [29] Zhang, L., Wang, W., Hayashi, Y., Jester, J.V., Birk, D.E., Gao, M., Liu, C.Y., Kao, W.W., Karin, M. and Xia, Y. (2003) A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. *EMBO J.* 22, 4443–4454.
- [30] Weston, C.R., Wong, A., Hall, J.P., Goad, M.E., Flavell, R.A. and Davis, R.J. (2004) The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis. *Proc. Natl. Acad. Sci. USA* 101, 14114–14119.
- [31] Hoshii, T., Sakumura, Y., Araki, M., Araki, K. and Yamamura, K. (2005) Analysis of abnormality in eye lid formation in LGR4 mutant mice. In: Proceedings of the 39th Annual Meeting of Japanese Society of Developmental Biologists, IP031.



Study on the quality control of cell therapy products Determination of *N*-glycolylneuraminic acid incorporated into human cells by nano-flow liquid chromatography/Fourier transformation ion cyclotron mass spectrometry

Noritaka Hashii^{a,b}, Nana Kawasaki^{a,b,*}, Yukari Nakajima^{a,b}, Masashi Toyoda^c,
Yoko Katagiri^c, Satsuki Itoh^a, Akira Harazono^a,
Akihiro Umezawa^c, Teruhide Yamaguchi^a

^a Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan

^b Core Research for Evolutional Science and Technology (CREST) of Japan Science and Technology Agency (JST),
4-1-8 Hon-cho, Kawaguchi, Saitama 332-0012, Japan

^c National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan

Received 6 February 2007; received in revised form 16 May 2007; accepted 21 May 2007

Available online 25 May 2007

Abstract

N-Glycolylneuraminic acid (NeuGc), an acidic nine-carbon sugar, is produced in several animals, such as cattle and mice. Since human cells cannot synthesize NeuGc, it is considered to be immunogenic in humans. Recently, NeuGc contamination was reported in human embryonic stem cells cultured with xenogeneic serum and cells, suggesting that possibly NeuGc may harm the efficacy and safety of cell therapy products. Sialic acids have been determined by derivatization with 1,2-diamino-4,5-methylenedioxybenzene (DMB) followed by liquid chromatography/mass spectrometry (LC/MS) and liquid chromatography/tandem mass spectrometry (LC/MS/MS); however, the limited availability of cell therapy products requires more sensitive and specific methods for the quality test. Here we studied the use of nano-flow liquid chromatography/Fourier transformation ion cyclotron resonance mass spectrometry (nanoLC/FTMS) and nanoLC/MS/MS for NeuGc-specific determination at a low femtomole level. Using our method, we found NeuGc contamination of the human cell line (HL-60RG cells) cultured with human serum. Our method needs only 2.5×10^3 cells for one injection and would be applicable to the determination of NeuGc in cell therapy products.

© 2007 Elsevier B.V. All rights reserved.

Keywords: *N*-Glycolylneuraminic acid; Nano-flow liquid chromatography; Fourier transformation ion cyclotron mass spectrometry; Cell therapy products

1. Introduction

Sialic acids are a family of acidic nine-carbon sugars found in the non-reducing terminal of *N*-linked and *O*-linked oligosaccharides of glycoproteins and glycolipids [1,2]. There are more than 30 members with different substitutions on the amino group at carbon 5 and on hydroxyl groups at carbons 4, 7, 8 and 9 [2–8]. *N*-Glycolylneuraminic acid (NeuGc), a 5-*N*-glycolylated sialic acid, is produced in several animals, such as cattle, horses, mice and rats [9]. Since human cells cannot

synthesize NeuGc due to mutation of the cytidine monophospho (CMP)-*N*-acetylneuraminic acid (NeuAc) hydroxylase gene [10,11], NeuGc is considered to be antigenic and to induce immunoreaction in humans [4,12,13].

Advances in biotechnology and cell culture techniques make it possible to administer human and animal cells directly to patients as cell therapy products. In cell therapy and tissue engineering, human embryonic stem (ES) cells are expected to be useful for the treatment of many diseases. Recently, it was reported that NeuGc is incorporated into ES cells from human and mouse feeder cells and cultivation media containing xenogeneic serum, such as fetal calf serum (FCS) [14,15]. Since NeuGc is a foreign component in humans, it is feared that NeuGc may harm the efficacy and safety of cell therapy products. To

* Corresponding author. Tel.: +81 3 3700 9074; fax: +81 3 3700 9084.

E-mail address: nana@nihs.go.jp (N. Kawasaki).

assess the adverse effects of NeuGc, it is necessary to quantify NeuGc in cell therapy products.

Sialic acids have been determined by labeling with 1,2-diamino-4,5-methylenedioxybenzene (DMB) followed by conventional high-performance liquid chromatography (HPLC) with fluorescent detection [16–20]. The femtomole level of sialic acid can be determined by fluorescent detection [19]. The use of liquid chromatography/mass spectrometry (LC/MS) and liquid chromatography/tandem mass spectrometry (LC/MS/MS) has more advantage in the identification of sialic acid species [18,20–22]. The derivatization of sialic acids with DMB has advantages of good separation of NeuGc from NeuAc in chromatography and enhancement of ionization efficiency in MS. However, more sensitive and specific methods are desired for the quality control of cell therapy products, since in many cases only a low number of cell products, approximately 1×10^6 to 1×10^8 , should be available for quality tests.

In this study, we studied the use of nano-flow liquid chromatography/Fourier transformation ion cyclotron resonance mass spectrometry (nanoLC/FTMS) and LC/MS/MS to achieve the sensitive and specific determination of NeuGc. The potential of the method for quality testing of cell therapy products was evaluated using substrain of human promyelocytic leukemia HL-60 cells (HL-60RG cells) as model cells. Using this method, we determined NeuGc in membrane fractions from HL-60RG cells cultured with FCS, human serum and serum-free medium.

2. Experimental

2.1. Materials

NeuGc and NeuAc were purchased from Nacalai Tesque (Kyoto, Japan). FCS and normal human serum were purchased from Dainippon Sumitomo Pharma (Osaka, Japan). RPMI1640 medium and ASF104 medium were purchased from Sigma-Aldrich (St. Louis, MO, USA) and Ajinomoto (Tokyo, Japan), respectively.

2.2. Cell culture

Substrain of human promyelocytic leukemia HL-60 cells (HL-60RG cells, JCRB Cellbank, Osaka, Japan) was cultured in RPMI1640 medium supplemented with 10% FCS, 100 unit/ml of penicillin and 100 μ g/ml of streptomycin under a humidified atmosphere of 95% air and 5% CO₂ at 37 °C. HL-60RG cells were replaced at 2×10^5 cells/100 mm dish in RPMI1640 medium supplemented with 10% FCS or 10% normal human serum, and in serum-free ASF104 medium. The media were replaced four times, and semi-confluent growth cells were harvested.

2.3. Fractionation of the membrane fraction

The cells were washed in phosphate buffer saline (PBS) supplemented with protease inhibitors (protease inhibitor mix

solution, Wako, Tokyo, Japan) three times. The washed cells (1×10^6) were suspended in 100 μ l of 0.25 M sucrose/10 mM Tris-HCl buffer (pH 7.4) containing protease inhibitors, and sonicated at 4 °C for 30 s, two times (40W, Bioruptor UCW-201, Tosyoudenki, Kanagawa, Japan). After the nuclei were removed by centrifugation at 4 °C, $450 \times g$ for 10 min, the mitochondria and lysosome fractions were removed by re-centrifugation at 4 °C, $20,000 \times g$ for 10 min. The membrane fractions were precipitated by ultracentrifugation at 4 °C, $100,000 \times g$ for 60 min. The membrane fractions were washed in 100 μ l of 150 mM ammonium acetate buffer (pH 7.4) and recovered by re-ultracentrifugation.

2.4. Derivatization of NeuGc and NeuAc with DMB reagent

The membrane fractions were sonicated in 250 μ l of H₂O and then incubated with 250 μ l of 4 M acetic acid (final concentration, 2 M) at 80 °C for 3 h. The released sialic acids were passed through a solid-phase extraction cartridge (SepPak C-18, Waters, Milford, MA, USA) with 2 ml of H₂O, dried under vacuum, and resolved in 50 μ l of H₂O. The solution was incubated with DMB according to the manufacturer's instruction (Takara, Tokyo, Japan), and the reaction mixture was applied on a solid-phase extraction cartridge (Envi-Carb C, Supelco, Bellefonte, PA, USA). After washing the cartridge with 2.5 ml of 5 mM ammonium acetate (pH 9.6) for desalting, the DMB-labeled sialic acids were eluted with 3 ml of 45% acetonitrile/5 mM ammonium acetate (pH 9.6). The collected fraction was freeze dried.

2.5. nanoLC/FTMS

DMB-labeled sialic acids were separated by HPLC using Paradigm MS4 (Michrom BioResource, Auburn, CA, USA) equipped with a reversed-phase C18 column (Magic C18, 50 mm \times 0.1 mm, 3 μ m, Michrom BioResource, Auburn, CA, USA). Elution was achieved using 0.1% formic acid/2% ac-




Fig. 1. EIC at m/z 426.13–426.17 and m/z 442.12–442.16 obtained by SIM (m/z 400–450) of DMB-NeuGc and DMB-NeuAc in the positive ion mode.




Fig. 2. (A) Typical MS spectrum of peak a. (B) MS/MS spectrum of $[M+H]^+$ (m/z 442.145) acquired from around peak a. (C) Typical MS spectrum of peak b. (D) MS/MS spectrum of $[M+H]^+$ (m/z 426.150) acquired from around peak b. (E) Fragmentation of DMB-NeuGc and DMB-NeuAc.




Fig. 3. Calibration curves of DMB-NeuGc ($r=0.9998$) and DMB-NeuAc ($r=0.9995$).

tonitrile (pump A) and 0.1% formic acid/80% acetonitrile (pump B) with a linear gradient of 10–90% of B in 30 min at a flow rate of 750 nl/min. On-line MS and MS/MS were performed using an Fourier transformation ion cyclotron resonance (FT)/ion trap (IT) type mass spectrometer (LTQ-FT, Thermo-Electron, San Jose, CA, USA) equipped with a nano-electrospray ion source (AMR, Tokyo, Japan). DMB-NeuAc and DMB-NeuGc were determined by selected ion monitoring (SIM) in the positive ion mode. The analytical conditions were set to 200 °C for capillary temperature, 1800 eV spray voltage, m/z 400–450 scan range, and 35% collision energy. The automatic gain control (AGC) value, which is adjusted for the amount of imported ions for FTMS, was set to 5×10^4 . Maximum injection times, which are the adjusted times of imported ions, for ITMS and FTMS, were set to 50 and 1250 ms, respectively.

2.6. Method validation

The linearity of the signal intensity peak area of DMB-NeuAc and DMB-NeuGc was assessed by injections of 0.0078–500 pmol DMB derivatives. Correlation coefficients were calibrated using a least-squares linear regression model. The detection limit (DL) and the quantification limit (QL) were calculated using the formulas $DL = 3.3 \times \sigma / \text{slope}$ (σ : average of noise on chromatograph) and $QL = 10 \times \sigma / \text{slope}$, respectively. Accuracy and precision were determined by measuring three samples, where NeuGc spiked at the concentration of 50 fmol to the membrane fraction of cells cultured in serum-free medium which contains no NeuGc before the derivatization of NeuGc with DMB. Accuracy was calculated by comparison of the mean peak area and the calibration curve. Precision was estimated by relative standard deviation (RSD) from three samples.




Fig. 4. Detection of DMB-NeuGc in the membrane fractions of HL-60RG cells (2.5×10^3) cultured with 10% FCS. (A) EIC at m/z 442.12–442.16 obtained by SIM. (B) Typical MS spectrum of peak a. (C) MS/MS spectrum of $[M+H]^+$ (m/z 442.145) acquired from around peak a.

3. Results and discussion

3.1. Analysis of NeuGc and NeuAc by nanoLC/FTMS

It was reported that DMB-NeuGc yielded its dehydrated ion (m/z 424) together with molecular ion (m/z 442) by MS in the positive ion mode [18,21]. To control the dehydration of molecular ion in the ion trap device, AGC value, which regulates the amount of ions trapped into ion trap device, was set to 5×10^4 (default value, 5×10^5). This value was also useful for the detection of molecular ion of DMB-NeuAc.

Using the AGC value at 5×10^4 , SIM (m/z 400–450) was carried out in the positive ion mode. When a mix-




Fig. 5. Detection of DMB-NeuAc in the membrane fractions of HL-60RG cells (2.5×10^3) cultured with 10% FCS. (A) EIC at m/z 426.13–426.17 obtained by SIM. (B) Typical MS spectrum of peak b. (C) MS/MS spectrum of $[M+H]^+$ (m/z 426.150) acquired from around peak b.

ture of DMB-NeuGc and DMB-NeuAc (2 pmol each) was subjected to nanoLC/MS, two peaks appeared at 14 min (peak a) and 15 min (peak b) on the extracted ion chromatogram (EIC) at m/z 426.13–426.17 and m/z 442.12–442.16 (Fig. 1).

As shown in Fig. 2A, the m/z values of molecular ions around 14 min (m/z 442.145) suggest the elution of DMB-NeuGc in peak a. The structure of the DMB derivative at peak a was confirmed by the product ion spectra acquired from $[M+H]^+$ (m/z 442.145) as a precursor ion (Fig. 2B). Product ions missing two and three molecules of H_2O were found at m/z 406 and 388 in MS/MS spectra. Ions losing three H_2O and glycolyl groups (m/z 313), cross-ring fragment ion (m/z 229) and fragment ion




Fig. 6. Levels of (A) NeuGc and (B) NeuAc in the membrane fraction of HL-60RG cells (2.5×10^3) cultured with 10% FCS, 10% human serum (HS) and serum-free medium. Values are the means \pm SD ($n=3$).

yielded by loss of formaldehyde (m/z 283) were also formed by MS/MS (Fig. 2E). The fragment pattern of the MS/MS spectrum from $[M+H]^+$ (m/z 442.145) was consistent with that of DMB-NeuGc in the previous report [21]. Fragments at m/z 406 and 388 are DMB-NeuGc characteristic ions, which could be used for specific determination of DMB-NeuGc. Likewise, peak b was identified as DMB-NeuAc by molecular ions (m/z 426.150) and their product ions (m/z 390, 372, 313, 283 and 229) formed by MS/MS of $[M+H]^+$ (m/z 426.150) as a precursor ion (Fig. 2C and D).

Calibration curves were prepared by the injection of DMB-NeuGc and DMB-NeuAc from 0.0078 to 500 pmol. The linearity of DMB-NeuGc and DMB-NeuAc was confirmed in the range of 0.0078–50 pmol with the regression equations of $Y=1.31 \times 10^6 X - 9028.5$ ($r=0.9998$) and $Y=2.03 \times 10^6 X - 21548.0$ ($r=0.9995$), respectively (Fig. 3). DL and QL of DMB-NeuGc were 8.6 and 26.3 fmol, and those of DMB-NeuAc were 5.6 and 16.9 fmol, respectively. The use of FT/MS gave an accuracy of 92.4% by eliminating contaminants by using accurate m/z values. The precision of this method for NeuGc was 7.3%. Compared to the former method, in which a micro or semi-micro column and the quadrupole mass spectrometer were used for the detection of picomole levels of DMB derivatives, SIM by using nanoLC/FTMS achieved the specific detection of DMB-derivatized sialic acids at a lower level. The

method using nanoLC/FTMS and nanoLC/MS/MS allows not only the determination of DMB-derivatives with similar sensitivity as the fluorescence detection but also the identification of sialic acid species.

3.2. Quantification of NeuAc and NeuGc in membrane fraction of HL-60RG cells

Using HL-60RG cells as model cells, the potential of this method for the quantification of NeuGc on the cell membrane was evaluated. The membrane fraction from cells (1×10^6) cultured with 10% FCS was prepared by ultracentrifugation. Sialic acids were released by treatment with 2M acetic acid at 80 °C for 3 h and derivatized with DMB. DMB derivatives (2.5×10^3 cells) were subjected to nanoLC/MS and nanoLC/MS/MS in SIM mode. As shown in Fig. 4A, some peaks appeared in EIC at m/z 442.12–442.16. Based on the retention time as well as the m/z value of molecular ion (m/z 442.145), peak a that appeared at 14 min was assigned to be a peak of NeuGc (Fig. 4B). Fig. 4C shows the MS/MS spectrum acquired from $[M+H]^+$ (m/z 442.145) as precursor. The NeuGc-characteristic ions at m/z 406 and 388 together with other product ions at m/z 313, 283 and 229 clearly indicate the presence of NeuGc in the membrane fraction of HL-60RG cells. In the EIC at m/z 426.13–426.17, the single peak was observed at 15 min (Fig. 5A). The molecular ion at m/z 426.150, and product ions at m/z 390, 372, 313, 283 and 229 acquired at 15.13 min suggest that DMB-NeuAc is eluted in peak b (Fig. 5B and C). The levels of NeuGc and NeuAc in the membrane fraction from HL-60RG cells (2.5×10^3 cells) cultured with 10% FCS were 55.4 ± 4.6 fmol and 13.5 ± 0.6 pmol, respectively (Fig. 6)

After the cultivation of HL-60RG cells with human serum for 10 days (medium was changed four times), NeuGc and NeuAc were determined by the proposed method. Fig. 7A shows the EIC at m/z 442.12–442.16 obtained by nanoLC/MS. In spite of cultivation in human serum, an obvious peak still appeared at 14 min. Molecular ion (m/z 442.145) and NeuGc-characteristic product ions found in the MS/MS spectrum acquired from the molecular ion clearly indicate the presence of NeuGc in the membrane fraction (Fig. 7B and C). The levels of NeuGc and NeuAc in cells (2.5×10^3) cultured in 10% human serum were 29.2 ± 2.4 fmol and 21.0 ± 1.4 pmol, respectively (Fig. 6).

In contrast, no significant peaks appeared in EIC at m/z 442.12–442.16 when HL-60RG cells were cultured in serum-free medium for 14 days (medium was changed four times). The level of NeuAc in cells cultured in serum-free medium was 20.5 ± 1.6 pmol (Fig. 6).

As shown in Figs. 4A and 7A, there are many different molecules detected at m/z 442.14–442.16 in the cells, which makes it difficult to determine a small amount of NeuGc in the membrane fraction by the low-resolution mass spectrometry. The DMB-NeuGc-specific detection was achieved by acquisition of both the accurate mass by FTMS and the characteristic product ions arisen from DMB-NeuGc by MS/MS.

Our method needs only 2.5×10^3 cells for one injection and is applicable to the determination of NeuGc in cell ther-




Fig. 7. Detection of DMB-NeuGc in the membrane fractions of HL-60RG cells (2.5×10^3) cultured with 10% human serum. (A) EIC at m/z 442.12–442.16 obtained by SIM. (B) Typical MS spectrum of peak a. (C) MS/MS spectrum of $[M+H]^+$ (m/z 442.145) acquired from around peak a.

apy products. The incorporation of dietary NeuGc into human serum has been reported by Tangvoranuntal et al. [23], which has raised concerns about NeuGc contamination of cell therapy products through cultivation with human serum. Although using our method, we demonstrated the existence of NeuGc in human cells cultured with human serum, NeuGc could not be detected in human cells cultured in serum-free medium in which no NeuGc exists. These results suggest the difficulty of avoiding NeuGc contamination of cell therapy products during the manufacturing process. Further study to assess the immunogenicity of incorporated NeuGc is necessary to ensure the safety and efficacy of cell therapy products, and our method is useful for the sensitive and quantitative analysis of NeuGc in cell therapy products.

Acknowledgements

This study was supported in part by a Grant-in-Aid from the Ministry of Health Labor and Welfare, and Core Research for the Evolutional Science and Technology Program, Japan Science and Technology Corp.

References

- [1] C. Traving, R. Schauer, *Cell Mol. Life Sci.* 54 (1998) 1330.
- [2] T. Angata, A. Varki, *Chem. Rev.* 102 (2002) 439.
- [3] A. Varki, *Glycobiology* 2 (1992) 25.
- [4] R. Schauer, *Adv. Carbohydr. Chem. Biochem.* 40 (1982) 131.
- [5] S. Kitazume, K. Kitajima, S. Inoue, S.M. Haslam, H.R. Morris, A. Dell, W.J. Lennarz, Y. Inoue, *J. Biol. Chem.* 271 (1996) 6694.
- [6] R. Schauer, J. Haverkamp, M. Wember, J.P. Kamerling, J.F. Vliegenthart, *Eur. J. Biochem.* 62 (1976) 237.
- [7] N. Kawasaki, S. Itoh, M. Ohta, T. Hayakawa, *Anal. Biochem.* 316 (2003) 15.
- [8] M. Nakano, K. Kakehi, M.H. Tsai, Y.C. Lee, *Glycobiology* 14 (2004) 431.
- [9] E.A. Muchmore, S. Diaz, A. Varki, *Am. J. Phys. Anthropol.* 107 (1998) 187.
- [10] A. Irie, S. Koyama, Y. Kozutsumi, T. Kawasaki, A. Suzuki, *J. Biol. Chem.* 273 (1998) 15866.
- [11] H.H. Chou, H. Takematsu, S. Diaz, J. Iber, E. Nickerson, K.L. Wright, E.A. Muchmore, D.L. Nelson, S.T. Warren, A. Varki, *Proc. Natl. Acad. Sci. U. S. A.* 95 (1998) 11751.
- [12] H. Higashi, M. Naiki, S. Matuo, K. Okouchi, *Biochem. Biophys. Res. Commun.* 79 (1977) 388.
- [13] J.M. Merrick, K. Zadarlik, F. Milgrom, *Int. Arch. Allergy Appl. Immunol.* 57 (1978) 477.
- [14] M.J. Martin, A. Muotri, F. Gage, A. Varki, *Nat. Med.* 11 (2005) 228.
- [15] A. Heiskanen, T. Satomaa, S. Tiitinen, A. Laitinen, S. Mannelin, U. Impola, M. Mikkola, C. Olsson, H. Miller-Podraza, M. Blomqvist, A. Olonen, H. Salo, P. Lehenkari, T. Tuuri, T. Otonkoski, J. Natunen, J. Saarinen, J. Laine, *Stem Cells* 25 (2007) 197.
- [16] A.E. Manzi, S. Diaz, A. Varki, *Anal. Biochem.* 188 (1990) 20.
- [17] S. Hara, M. Yamaguchi, Y. Takemori, K. Furuhata, H. Ogura, M. Nakamura, *Anal. Biochem.* 179 (1989) 162.
- [18] M. Bardor, D.H. Nguyen, S. Diaz, A. Varki, *J. Biol. Chem.* 280 (2005) 4228.
- [19] M. Ito, K. Ikeda, Y. Suzuki, K. Tanaka, M. Saito, *Anal. Biochem.* 300 (2002) 260.
- [20] F.N. Lamari, N.K. Karamanos, *J. Chromatogr. B* 781 (2002) 3.
- [21] A. Klein, S. Diaz, I. Ferreira, G. Lamblin, P. Roussel, A.E. Manzi, *Glycobiology* 7 (1997) 421.
- [22] H.H. Chou, T. Hayakawa, S. Diaz, M. Krings, E. Indriati, M. Leakey, S. Paabo, Y. Satta, N. Takahata, A. Varki, *Proc. Natl. Acad. Sci. U. S. A.* 99 (2002) 11736.
- [23] P. Tangvoranuntakul, P. Gagneux, S. Diaz, M. Bardor, N. Varki, A. Varki, E. Muchmore, *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 12045.

Ways for a Mesenchymal Stem Cell to Live on Its Own: Maintaining an Undifferentiated State Ex Vivo

Masashi Toyoda, Hidekazu Takahashi, Akihiro Umezawa

Department of Reproductive Biology, National Institute for Child Health and Development, Tokyo, Japan

Received April 3, 2007; accepted May 2, 2007

Abstract

Like all stem cells, mesenchymal stem cells (MSC) must balance self-renewal and differentiation. Complex regulatory mechanisms are required to keep stem cells in an undifferentiated, self-renewing state and to mediate their subsequent differentiation and proliferation. In this review, we discuss how adequate numbers of MSC can be maintained in culture. In particular, we focus on identification of the cell culture conditions needed to maintain general, nonspecific potential as a stem cell over time and through replication. It would be extremely advantageous to be able to maintain MSC populations in a completely undifferentiated state and to determine and switch on specific differentiation as and when required.

Int J Hematol. 2007;86:1-4. doi: 10.1532/IJH97.07055

© 2007 The Japanese Society of Hematology

Key words: Mesenchymal stem cells; Cell culture; Differentiation; Cell growth; Senescence

1. Introduction

Mesenchymal stem cells (MSC) are attracting a great deal of attention, because they represent a valuable source of cells for use in regenerative medicine [1]. Use of MSC entails no ethical or immunologic problems, and they provide an excellent model of cell differentiation in biology. Not surprisingly, mesenchymal cell biology is a complex and rapidly evolving field. Critical unanswered questions remain: What defines an MSC (as opposed to just a mesenchymal cell), and what provides MSC with their unique properties?

Stem cell biology is based on the principle that any tissue may contain cells that possess the potential for both self-renewal and differentiation into one or more cell types. Mesenchymal cells are derived from an organ's supporting tissue, as opposed to parenchyma or the supporting framework of an animal organ, which typically consists of connective tissue. Among these cells exist stem cells, which have two basic processes, ie, self-renewal and differentiation. MSC were first

discovered in 1976 by Friedenstein, who described clonal, plastic-adherent cells from bone marrow that provided a physical scaffold for hematopoiesis and that could differentiate into osteoblasts, chondrocytes, and adipocytes *in vitro* [2]. To date, investigators have demonstrated that MSC *per se* can be recovered from a variety of adult tissues and have the capacity to differentiate into a variety of specific cell types [3-8]. The mesenchymal phenotype can be maintained under optimal culture conditions, and MSC *in vitro* are recognized as adherent fibroblastic cells with a generally spindle shape, although some candidate populations of cells are more spherical with few spindle-shaped cells [9]. This heterogeneous population is too "crude" to consist solely of MSC. Although MSC can be harvested from a variety of tissues and have multipotency (ie, the capability to differentiate into numerous tissue lineages, including myoblasts, cardiomyocytes, osteoblasts, adipocytes, chondrocytes, and possibly even neural cells), MSC populations cannot easily be induced to differentiate into one lineage at the same time. There are some cell populations that behave like progenitor cells with monopotency or bipotency. In this review, we describe how MSC derived from a variety of tissues have tissue-specific characteristics and discuss optimal culture conditions that can allow the cells both to keep proliferating in an undifferentiated, self-renewing state and to permit mediation of their future differentiation.

Correspondence and reprint requests: Akihiro Umezawa, Department of Reproductive Biology, National Institute for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo, 157-8535, Japan; 81-3-5494-7047 (e-mail: umezawa@1985.jukuin.keio.ac.jp).

2. MSC Optimally Require Their Original Milieu

Stem cells are indispensable entities in most multicellular organisms in that they are responsible for forming tissues during early development and for maintaining them in the adult stage. Because all somatic stem cells, including MSC, have the same genetic material, every cell type has the potential to express a stem cell phenotype under specific conditions; that is, tissue-specific flexibility is inherent. Mesenchymal cells, of which connective tissue is mainly composed, do not develop into a tissue or an organ. The cells synthesize the extracellular matrix by themselves and in vitro establish favorable environments for growth. Mesenchymal cell cultures can be made from suspensions of cells dissociated from tissues, and microscopical and biochemical analyses facilitate exploration of the effects of adding or removing specific molecules, such as hormones or growth factors.

Cells vary in their needs in a cell type-specific manner, and cells can therefore be categorized or defined by their requirements. Bone marrow-derived MSC, for example, can be compared with umbilical cord blood-derived MSC. Several methods are available for distinguishing between these two types of cells. One such method is flow cytometric analysis of markers that appear on the surfaces of the cells. Some surface marker characteristics of bone marrow-derived MSC are the same as those of cord blood-derived MSC (eg, CD29⁺, CD44⁺, CD55⁺, CD59⁺, CD34⁺, and CD117⁺ [10-12]). On the other hand, the CD90 and CD133 markers can be used to distinguish cord blood-derived cells from bone marrow-derived cells, because these markers are expressed in multipotent marrow-derived cells but not in cord blood-derived cells [12]. As yet, no surface markers have been identified that define MSC. Another method is complementary DNA microarray/chip technology. Because of the logical connection between gene expression and cell function, gene expression patterns can predict the variation in cell phenotypes and reveal novel phenotypic aspects of the cells and tissues studied. In mesenchymal cell culture, expression of genes encoding growth factor receptors is an important factor in microarray analysis-based investigations of the effects of growth factors, because cells dissociated from different tissues, such as bone marrow and cord blood, have different responses to growth factors (Table 1). This response affects differentiation potential. Bone marrow-derived cells can differentiate into osteoblasts, chondrocytes, cardiomyocytes, adipocytes, skeletal myocytes, and neural cells and do so according to the specific cell culture conditions, whereas cord blood-derived cells exhibit only osteogenic and adipogenic potential under the same conditions.

How can the microenvironment, culture conditions, or growth factors dictate the identity of MSC and their production of different progeny? Serum plays a critical role in the growth of cells in vitro by providing components such as amino acids, lipids, growth factors, vitamins, hormones, and attachment factors, by acting as a pH buffer, and by providing protease inhibitors. Most media for mesenchymal cell culture include a poorly defined mixture of macromolecules in the form of fetal calf serum; however, the use of serum for MSC culture makes it difficult to know which specific macromolecules a particular type of cell requires for survival and normal

function. This difficulty led to the development of serum-free chemically defined media. In addition to the usual molecules, such specialized media will need to contain essential growth factors that the MSC require in culture. The primary requirements of MSC in culture reflect the origin of the cells; that is, investigators have to try to recreate the specific native tissue/organ milieu of the cells' origin. Identification of a means to create an "Elysium" or ideal stress-free native environments for cultivating and maintaining MSC will bestow significant benefits for future stem cell therapeutics.

3. The Paradox of Cell Growth versus Life Span

In cell culture it is important not only to remove animal serum from the culture medium (for reasons of medical safety with respect to infectious diseases [13-15]) but also to obtain large numbers of cells for use in therapy. Cells must be propagated in vitro to obtain the large numbers needed for biomedical procedures; however, Hayflick's problem is unavoidable in normal cells [16,17]. Most vertebrate cells stop dividing after a finite number of divisions in culture, a process called senescence [17,18]. Senescence is classified into two categories: "stress-induced premature senescence" (or "telomere-independent senescence") and "replicative senescence" (or "telomere-dependent senescence") [19-21]. Marrow-derived mesenchymal cells divide approximately 25 to 40 times [11,22] in culture before they cease dividing or reach senescence (M0, mortality stage 0, ie, premature senescence), whereas a few cells that overcome this step restart proliferation but stop dividing again in replicative senescence (M1) (Figure 1).

To resolve these problems, investigators can extend the life span of bone marrow-derived MSC via retroviral transduction of human telomerase reverse transcriptase (hTERT) and human papillomavirus type 16 E6 and/or E7 genes [11]. A significant observation is that an increase in telomerase

Table 1.
Reactivities of Mesenchymal Stem Cells to Growth Factors*

	MSC	UCB	UE6E7T-12	UE7T-13
PDGF	+++	+++	+++	+++
EGF	+++	++	+++	++
aFGF	+++	++	++	+
bFGF	+++	+++	+++	++
LIF	-	+	++	+
VEGF	+	+	+	-
HGF	-	-	+	-
IGF-1	+	+	-	-
IL-1	-	-	-	++
IL-6	-	-	+	-

*Plus and minus symbols show the strength of growth factor reactivity based on cell proliferation. MSC indicates human bone marrow-derived mesenchymal stem cells; UCB, human umbilical cord blood-derived mesenchymal stem cells; UE6E7T-12 and UE7T-13, MSC transduced with human papillomavirus type 16 E6 and/or E7, and human telomerase reverse transcriptase (hTERT); PDGF, platelet-derived growth factor; EGF, epidermal growth factor; aFGF, acidic fibroblast growth factor; bFGF, basic FGF; LIF, leukemia inhibitory factor; VEGF, vascular endothelial growth factor; IGF-1, insulin-like growth factor 1; IL-1, interleukin 1.




Figure 1. Life span of mesenchymal stem cells. Marrow-derived mesenchymal cells divide approximately 25 to 40 times in culture before they cease dividing or reach senescence (M0, mortality stage 0, ie, premature senescence). Some cells that overcome this step restart proliferation but stop dividing again in replicative senescence (M1). The system in which the p16ink4a/RB pathway is inhibited and telomerase is activated via transduction of *bmi-1*, human papillomavirus type 16 E6, E7, and hTERT is efficient in extending cellular life span.

activity produced via hTERT induction is insufficient to prolong the life span of bone marrow-derived MSC [23], because p16ink4a, a cyclin-dependent kinase inhibitor, is up-regulated [22]. This up-regulation of p16ink4a is directly linked to an increase in the number of cell doublings [24]. Inhibition of the p16/Rb pathway is sufficient to prolong the life span of cells in cultures of marrow-derived cells [11,22]. The p16ink4a/RB braking pathway leading to senescence can be inhibited by inducing the human papillomavirus type 16 E7 gene and/or *bmi-1*. *bmi-1*, one of the polycomb-group genes, has been used to inhibit p16ink4a transcription in order to prolong life span [25,26]. In addition, induction of the human papillomavirus type 16 E6 gene, which inhibits the p53 pathway, allows long-term cultivation of these cells. This system, in which the p16ink4a/RB pathway is inhibited and telomerase is activated, is highly efficient in extending the life span of bone marrow-derived MSC [23]. The life span of cord blood-derived MSC can be extended with hTERT alone [12].

Cell characteristics remain unaffected by *bmi-1*, E6, E7, and hTERT. The surface markers and the growth factor reactivities of transduced cells are unchanged (Table 1), and the transduced cells maintain their capabilities as stem cells [12,22]. So, can multipotent MSC with an extended life span be made available for cell-based therapy? It appears that transduced cells do not transform according to classic criteria: they do not generate a tumor in immunosuppressed interleukin 2 receptor knock-out NOD-SCID mice [22], they do not form foci *in vitro*, and they stop dividing after confluence. We cannot rule out the possibility, however, that gene-transduced bone marrow cells will become tumorigenic in patients several decades after commencement of cell therapy. What must be taken into account is that even when nononcogenic genes are introduced for cell-based therapy to increase cell growth and

prolong life span, cases of leukemia have occurred in severe combined-immunodeficient patients treated with gene-modified lymphocytes [27]. Because of these failures, more time will be required before gene-modified cells can be used for regenerative medicine. Alleviation of culture stress is thus necessary to prolong the life span of mesenchymal cells.

Signaling from growth factor receptors caused by exogenously added growth factors induces p16ink4a protein through p38 and should selectively inhibit the prolongation of the cell life span without affecting growth factor-dependent cell proliferation through the classic Mek-Erk MAPK pathway (Figure 2A). Excessive stimulation by growth factors can be a cell senescence inducer, like oxidative stress and "culture shock" [28,29]. Growth factor-dependent acceleration of premature senescence or growth arrest is rather unexpected and unfavorable and is analogous to pressing down on the gas and brake pedals simultaneously [30,31]. Up-regulation of cell growth without affecting the cell life span, a key future goal of any cell-based therapy, would thus be a trade-off and create a fundamental quandary (Figures 2B and 2C).

4. Conclusion

Mammalian aging is associated with reduced regenerative capacity in tissues that contain stem cells. The aging process has been proposed to be at least partially caused by the senescence of progenitors with age; however, whether genes associated with senescence functionally contribute to physiological declines in progenitor activity has not yet been tested. Quantitative and qualitative changes do occur in stem cell populations with age [32-36]. The transition of multipotent stem cells to a more specific differentiated state is associated with simultaneous activation or inactivation of specific genes, and the promiscuous expression of many lineage-specific genes in primitive stem cells gradually decreases as cells reach a more mature state. Covalent modification




Figure 2. Signaling cascade and growth curves of mesenchymal stem cells for cell therapy. A, Scheme of the signaling cascade induced by stimuli leading to cell proliferation and senescence. B, Cell proliferation and the life span of mesenchymal cells are inversely correlated. C, Idealized cell growth profile in a stress-free medium. An ideal medium will help promote cell growth without affecting cellular aging.

includes acetylation, methylation, phosphorylation, and ubiquitination [37], and epigenetic regulation plays important roles in regulating gene expression. Consequently, the aging process influences stem cell-specific gene transcription. MicroRNA have recently been reported to be engaged in this regulation [38]. The goal of developing a clinically suitable medium for proliferating mesenchymal cells without affecting multipotency ex vivo appears feasible (Figure 2C), and its achievement should be beneficial to patients requiring an autologous or allogeneic transplant.

References

- Alhadlaq A, Mao JJ. Mesenchymal stem cells: isolation and therapeutics. *Stem Cells Dev.* 2004;13:436-448.
- Friedenstein AJ. Precursor cells of mechanocytes. *Int Rev Cytol.* 1976;47:327-359.
- Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. *J Clin Invest.* 1999;103:697-705.
- Umezawa A, Maruyama T, Segawa K, Shaddock RK, Waheed A, Hata J. Multipotent marrow stromal cell line is able to induce hematopoiesis in vivo. *J Cell Physiol.* 1992;151:197-205.
- Owen M. Marrow stromal stem cells. *J Cell Sci Suppl.* 1988;10:63-76.
- Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. *J Cell Biochem.* 1997;64:295-312.
- Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. *Science.* 1999;284:143-147.
- Sekiya I, Larson BL, Vuorio JT, Cui JG, Prockop DJ. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). *J Bone Miner Res.* 2004;19:256-264.
- Horwitz EM. Mesenchymal cells: a basic review, 2002. Available at: http://www.celltherapy.org/files/documents/2005_Information_Booklet_-_Mesenchymal.doc. Accessed May 8, 2007.
- Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. *Blood.* 2004;103:1669-1675.
- Takeda Y, Mori T, Imabayashi H, et al. Can the life span of human marrow stromal cells be prolonged by bmi-1, E6, E7, and/or telomerase without affecting cardiomyogenic differentiation? *J Gene Med.* 2004;6:833-845.
- Terai M, Uyama T, Sugiki T, Li XK, Umezawa A, Kiyono T. Immortalization of human fetal cells: the life span of umbilical cord blood-derived cells can be prolonged without manipulating p16^{INK4a}/RB braking pathway. *Mol Biol Cell.* 2005;16:1491-1499.
- Lennon DP, Haynesworth SE, Young RG, Dennis JE, Caplan AI. A chemically defined medium supports in vitro proliferation and maintains the osteochondral potential of rat marrow-derived mesenchymal stem cells. *Exp Cell Res.* 1995;219:211-222.
- Wiles MV, Johansson BM. Embryonic stem cell development in a chemically defined medium. *Exp Cell Res.* 1999;247:241-248.
- Yao CL, Chu IM, Hsieh TB, Hwang SM. A systematic strategy to optimize ex vivo expansion medium for human hematopoietic stem cells derived from umbilical cord blood mononuclear cells. *Exp Hematol.* 2004;32:720-727.
- Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. *Exp Cell Res.* 1961;25:585-621.
- Campisi J. From cells to organisms: can we learn about aging from cells in culture? *Exp Gerontol.* 2001;36:607-618.
- Wei W, Sedivy JM. Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures. *Exp Cell Res.* 1999;253:519-522.
- Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. *Proc Natl Acad Sci U S A.* 1992;89:10114-10118.
- Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. *Exp Gerontol.* 1992;27:383-389.
- Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. *Science.* 1998;279:349-352.
- Mori T, Kiyono T, Imabayashi H, et al. Combination of hTERT and bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic potential. *Mol Cell Biol.* 2005;25:5183-5195.
- Okamoto T, Aoyama T, Nakayama T, et al. Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells. *Biochem Biophys Res Commun.* 2002;295:354-361.
- Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. *Proc Natl Acad Sci U S A.* 1996;93:13742-13747.
- Haga K, Ohno S, Yagawa T, et al. Efficient immortalization of primary human cells by p16^{INK4a}-specific short hairpin RNA or Bmi-1, combined with introduction of hTERT. *Cancer Sci.* 2007;98:147-154.
- Kim RH, Kang MK, Shin KH, et al. Bmi-1 cooperates with human papillomavirus type 16 E6 to immortalize normal human oral keratinocytes. *Exp Cell Res.* 2007;313:462-472.
- Haccin-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science.* 2003;302:415-419.
- Sherr CJ, DePinho RA. Cellular senescence: mitotic clock or culture shock? *Cell.* 2000;102:407-410.
- Toussaint O, Medrano EE, von Zglinicki T. Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. *Exp Gerontol.* 2000;35:927-945.
- Ramirez RD, Morales CP, Herbert BS, et al. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. *Genes Dev.* 2001;15:398-403.
- Raucci A, Laplantine E, Mansukhani A, Basilico C. Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. *J Biol Chem.* 2004;279:1747-1756.
- Morrison SJ, Wandycz AM, Akashi K, Globerson A, Weissman IL. The aging of hematopoietic stem cells. *Nat Med.* 1996;2:1011-1016.
- Harrison DE, Zhong RK, Jordan CT, Lemischka IR, Astle CM. Relative to adult marrow, fetal liver repopulates nearly five times more effectively long-term than short-term. *Exp Hematol.* 1997;25:293-297.
- Kim M, Moon HB, Spangrude GJ. Major age-related changes of mouse hematopoietic stem/progenitor cells. *Ann N Y Acad Sci.* 2003;996:195-208.
- Henckaerts E, Langer JC, Snoeck HW. Quantitative genetic variation in the hematopoietic stem cell and progenitor cell compartment and in lifespan are closely linked at multiple loci in BXD recombinant inbred mice. *Blood.* 2004;104:374-379.
- Liang Y, Van Zant G, Szilvassy SJ. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. *Blood.* 2005;106:1479-1487.
- Bandyopadhyay D, Medrano EE. The emerging role of epigenetics in cellular and organismal aging. *Exp Gerontol.* 2003;38:1299-1307.
- Oakley EJ, Van Zant G. Unraveling the complex regulation of stem cells: implications for aging and cancer. *Leukemia.* 2007;21:612-621.